Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- SPRINT.ST
- Price
- 1.47
- Stock movement up
- +0.01 (0.68%)
- Company name
- Sprint Bioscience AB
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 155.11M
- Ent value
- 159.53M
- Price/Sales
- 3.13
- Price/Book
- 25.58
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 4.90
- PEG
- -
- EPS growth
- -28.57%
- 1 year return
- -8.07%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-12-12
DIVIDENDS
SPRINT.ST does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 3.13 |
| Price to Book | 25.58 |
| EV to Sales | 3.22 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 105.52M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | - |
| Gross profit (TTM) | - |
| Operating income (TTM) | - |
| Net income (TTM) | - |
| EPS (TTM) | - |
| EPS (1y forward) | 0.30 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 10.95M |
| Net receivables | 6.45M |
| Total current assets | 17.40M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 21.44M |
| Accounts payable | 3.30M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 15.37M |
| Total liabilities | 15.37M |
| Shareholder's equity | 6.06M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | - |
| Capital expenditures (TTM) | - |
| Free cash flow (TTM) | - |
| Dividends paid (TTM) | - |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.44 |
| Daily high | 1.48 |
| Daily low | 1.38 |
| Daily Volume | 348K |
| All-time high | 51.54 |
| 1y analyst estimate | 2.50 |
| Beta | -0.77 |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 11 Feb 2026 |
Downside potential
Loading...
Downside potential data
| SPRINT.ST | S&P500 | |
| Current price drop from All-time high | -97.15% | -1.08% |
| Highest price drop | -99.21% | -19.00% |
| Date of highest drop | 2 Jun 2025 | 8 Apr 2025 |
| Avg drop from high | -98.06% | -2.64% |
| Avg time to new high | - | 6 days |
| Max time to new high | 296 days | 89 days |
COMPANY DETAILS
Marketcap
155.11M
Marketcap category
Small-cap
Description
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden.
Employees
38
Investor relations
-
SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
The company, which invested heavily in oncology in recent years, has now put more than $400 million on the table to access a Sprint Bioscience drug targeting “TREX1.”
November 25, 2025